BRAND NAME / COMPANY / REIMBURSEMENT AND LOGISTICS PROGRAM (ORIGINAL MARKET DATE)

Simponi®/Janssen/BioAdvance® (2013)

APPROVED CLINICAL INDICATIONS

(may vary within provinces – refer to local patient support program)

Ulcerative colitis.

CLASS

Monoclonal antibody interleukin (IL)-23 inhibitor

ACTION

Targets IL-23 protein receptor, which is one of the proteins responsible for inflammation. Blocking this receptor contributes to reducing inflammation.